CEACAM5 and malignant colon neoplasm: For the proportion of abnormal expression of these four markers in early stage colon cancer patients, sDC-SIGN (81.3%) and sDC-SIGNR (40.5%) were higher than for CEA (21.3%) or CA19-9 (4.5%) (Table 1).